TrialCancer2020

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

Robert J Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.